February 3, 1994, now abandoned, the teachings of which are incorporated herein by reference.--.

IN THE CLAIMS:

Page 142, claim 17, lines 3-4, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Page 143, claim 18, line 3, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Page 143, claim 19, line 4, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Page 143, claim 20, line 3, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Page 143, claim 21, line 4, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Page 143, claim 22, line 9, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Pages 143-144, claim 23, lines 4-5, please change "claims 1-15" to --claims 1, 8, 11 or 13--;

Page 144, claim 24, line 2, please change "claims 1-15" to --claims 1, 8, 11 or 13--.

REMARKS

Applicant respectfully requests that the subject Continuation Application be preliminarily amended as provided in the foregoing amendment prior to calculation of the filing fees.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-24. (Canceled)

25. (Currently amended) A method for treating a disorder of the nervous system in which the pathophysiology of the disorder involves excessive or inappropriate release of a neurotransmitter from neuronal cells, comprising administering to a mammal exhibiting symptoms of the disorder or susceptible to the disorder an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, ~~or a substituted or unsubstituted aralkyl having at least about 5 ring atoms,~~ or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R^1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

26. (Previously presented) A method of claim 25 wherein at least one of R and R^1 is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

27. (Previously presented) A method of claim 25 wherein both R and R^1 are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

583364_1

28. (Canceled)

29. (Previously presented) A method of claim 25 wherein R and R^1 are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

30. (Previously presented) A method of claim 25 wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;

N-(5-acenaphthyl)-N-benzylguanidine;

N-(3-acenaphthyl)-N-benzylguanidine;

N-(5-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;

N-(3-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;

N-(4-cyclohexylphenyl)-N-(4-*iso*propylbenzyl)guanidine;

N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;

N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;

N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;

N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;

N-(5-acenaphthyl)-N-(cinnamyl)guanidine;

N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;

N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;

and pharmaceutically acceptable salts thereof.

31. (Previously presented) A method of any one of claims ~~25 through 30~~ wherein the mammal is suffering from a neurodegenerative disorder.

32. (Previously presented) A method for treating a mammal suffering from or susceptible to a neurodegenerative disease, comprising administering to the mammal an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R^1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

33. (Previously presented) A method of claim 32 wherein at least one of R and R^1 is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

9 7
34. (Previously presented) A method of claim 32 wherein both R and R^1 are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

35. (Canceled)

10 7
36. (Previously presented) A method of claim 32 wherein R and R^1 are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

11 7
37. (Previously presented) A method of claim 32 wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;
N-(5-acenaphthyl)-N-benzylguanidine;
N-(3-acenaphthyl)-N-benzylguanidine;
N-(5-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(3-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(4-cyclohexylphenyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;
N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;

N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;

N-(5-acenaphthyl)-N-(cinnamyl)guanidine;

N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;

N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;

and pharmaceutically acceptable salts thereof.

7-9 10-11

12
~~38~~. (Previously presented) A method of any one of claims ~~32-34~~ or ~~36-37~~ wherein the neurodegenerative disease is Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Down's Syndrome, Korsakoff's disease, olivopontocerebellar atrophy, HIV-induced dementia or blindness, multi-infarct dementia or diabetic neuropathy.

13
~~39~~. (Previously presented) A method of treating a disease in which the pathophysiology of the disease involves inappropriate cellular secretion comprising administering to a mammal suffering from or susceptible to the disease an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R^1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring

members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

14 13
~~40~~. (Previously presented) A method of claim ~~39~~ wherein at least one of R and R^1 is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

15 13
~~41~~. (Previously presented) A method of claim ~~39~~ wherein both R and R^1 are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

42. (Canceled)

16 13
~~43~~. (Previously presented) A method of claim ~~39~~ wherein R and R^1 are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

17 13
~~44~~. (Previously presented) A method of claim ~~39~~ wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;
N-(5-acenaphthyl)-N-benzylguanidine;
N-(3-acenaphthyl)-N-benzylguanidine;
N-(5-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(3-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(4-cyclohexylphenyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;
N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;
N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;
N-(5-acenaphthyl)-N-(cinnamyl)guanidine;
N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;
N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;
and pharmaceutically acceptable salts thereof.

18. (Previously presented) A method of modulating the release of excess endogenous neurotransmitters from a mammal comprising administering to the mammal an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R^1 is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring

members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

19 18
~~46~~. (Previously presented) A method of claim ~~45~~ wherein at least one of R and R^1 is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

20 18
~~47~~. (Previously presented) A method of claim ~~45~~ wherein both R and R^1 are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

48. (Canceled)

21 18
~~49~~. (Previously presented) A method of claim ~~45~~ wherein R and R^1 are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

22 18
~~50~~. (Previously presented) A method of claim ~~45~~ wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;
N-(5-acenaphthyl)-N-benzylguanidine;
N-(3-acenaphthyl)-N-benzylguanidine;
N-(5-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(3-acenaphthyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(4-cyclohexylphenyl)-N-(4-*iso*propylbenzyl)guanidine;
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;

N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;

N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;

N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;

N-(5-acenaphthyl)-N-(cinnamyl)guanidine;

N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;

N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;

and pharmaceutically acceptable salts thereof.

51-59. (Canceled)